Between the Lines is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from oncologists and advanced practice providers on published, peer-reviewed content.
Between the Lines: Recent Updates in Treatment and Strategies for Managing Adverse Events in Multiple Myeloma
Cabozantinib Lengthens PFS for Extrapancreatic NETs of GI Origin
Preoperative Sintilimab with Chemoradiotherapy Boosts Response Rates in Resectable Esophageal Cancer
22% of Community Providers Reported Biomarker Testing in Gastric/GEJ Cancers
Tislelizumab Plus Chemotherapy Demonstrates Strong Anti-Tumor Activity in ESCC